Institut Pasteur

Other

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Institut National De La Recherche Scientifique

Centre National De La Recherche Scientifique

The United States of America As Represented by the Secretary of

Institut National De La Sante Et De La Recherche Medicale

The United States of America As Represented by the Department of Health

Institut Pasteur and Centre National De La Recherche Scientifique

Solange Chamaret

Luc Montagnier

Christine Rouzioux

Jean-Claude Chermann

Francoise Barre-Sinoussi

Willy Rozenbaum

Francoise Rey

Charles Dauguet

Claudine Axler-Blin

Marc Alizon

Jacqueline Gruest

Pierre Sonigo

Robert C Gallo

Mikulas Popovic

Marie-Therese Nugeyre

Francoise Brun-Vezinet

Mangalasseril G Sarngadharan

Denise Guetard

Mireille Guyader

Christine Katlama

Marianne Rey

Simon Wain-Hobson

Stewart T Cole

Bernard Krust

Francois Clavel

Fran&ccedil;ois Clavel

Marie-Theresa Nugeyre

Francois Brun-Vezinet

Jacques Gruest, Legal Representative

Francoise Vezinet-Brun

Pierre Tiollais

Oliver Danos

François Clavel

Wesley Loren Cosand

Cole Stewart

Olivier Danos

Francedillaois Clavel

Fran&ccedil;oise Brun-Vezinet

Claude Granier

Raymond L Houghton

Stephane Ferris

Francoise Vezinet-Bruil

Francedillaoise Barre-Sinoussi

Jean-Marc Sabatier

Jurphaar V Rietschoten

El M Bahraoui

Herve Rochat

Marie Theresa Nugeyre

Jean C Chermann

Francedillaoise Brun-Vezinet

Andrew J Watson

Mangalasseril G Sarngadhar

G Sarngadharan

Fran&ccedil;oise Barre-Sinoussi

Luc Montangnier

Françoise Brun-Vezinet

Françoise Barre-Sinoussi

The invention relates to a composition comprising at least one antigen, wherein the antigen is a protein or glycoprotein of a HIV-2 virus, wherein the HIV-2 virus has infectious properties with respect to human T4 lymphocytes and the essential morphological or immunological property of at least one of the retroviruses deposited at the CNCM under No. I-502, I-532, I-642, and I-643. It also relates to a process for the production of HIV-2 retrovirus antigens by lysing cells infected with the virus or lysing purified virus and recovering the antigens.

HIV-2 antigen compositions

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.

DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1)

This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA

This invention provides antibodies which bind with p12 and p18 proteins of a human immunodeficiency virus type 1 (HIV-1), antibodies which bind with immune complexes comprising p12 or p18 proteins of HIV-1, mixtures of antibodies which bind with p12, p15, p18, p25, p36, p42, and p80 proteins of HIV-1, mixtures of antibodies which bind with immune complexes comprising the HIV-1 proteins, immune complexes comprising p12 or p18 proteins of HIV-1, and methods for production of antibodies against p2 or p18 proteins of HIV-1.

Antibodies which bind with proteins of human immunodeficiency virus type 1 (HIV-1), and immune complexes comprising proteins of HIV-1

The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.

Retrovirus capable of causing AIDS, means and methods for detecting it in vitro

Method for preparing a viral extract containing HIV-II RNA

The identification, separation, purification, and propagation of the HIV-1 virus is provided. Moreover, the preparation of antigens from HIV-1 is further provided. The identification of HIV-1 involves the purification of a virus sample from lymphocytes and contacting the sample with antibodies, which bind to HIV-1 viruses, is provided. The propagation of HIV-1 virus involves infecting uninfected T lymphocytes with the virus. Moreover, the preparation of antigens from HIV-1 involves the separation of protein components of a purified HIV-1 virus under denaturing conditions.

Methods for the propagation, isolation, identification, and preparation of human immunodeficiency virus type 1 (HIV-1)

Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.

Antibody directed against HIV-1 P25 antigen

The molecular cloning and characterization of a novel human retrovirus, designated lymphadenopathy-associated virus, or LAV, is disclosed. LAV was originally isolated from a patient with acquired immune deficiency syndrome (AIDS). A cloned LAV complementary DNA (cDNA) was used to screen a library of recombinant phages constructed from the genomic DNA of LAV-infected T lymphocytes. The nucleotide sequence of an insert obtained from the recombinant phage clone &lgr;J19 was ascertained through M13 shotgun cloning and the dideoxy chain termination sequencing method. The env coding region was identified and various hydrophilic peptides obtained therefrom. These peptides correspond to amino acids 551-577, 594-603, 621-630, 657-679, and 719-758 of the LAV envelope glycoprotein. These peptides should provide suitable diagnostic reagents for the detection LAV-specific antibodies and for the generation of LAV-specific immunological reagents.

Nucleic acids and peptides of human immunodeficiency virus type (HIV-1)

Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recongize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS.

Methods and kits employing LAV antigens for the detection of HIV-1-specific antibodies

The invention concerns a retrovirus extract containing a p25 protein which recognizes immunologically sera of patients afflicted with lymphadenopathy syndrom (LAS) or acquired immune deficiency syndrom (AIDS). It relates to a method and kit for in vivo assay of LAS or AIDS involving contacting sera from patients to be diagnosed for such diseases with said retrovirus extract and by detecting the immunological reaction, if any.

Methods and kits for detecting antibodies against an HIV variant

Peptide sequences are disclosed which immunologically mimic proteins encoded by the env and gag regions of LAV-2, a retrovirus associated with AIDS. The peptide can be used in various specific binding assays to detect the presence of antibodies to LAV-2 in individuals previously exposed to the virus. The peptides enable one to distinguish the presence of antibodies to LAV-2 from antibodies to HIV-1.

Synthetic HIV-2 gag and env oligopeptides reactive with HIV-2 specific antibodies

The claimed invention is directed toward in vitro methods for the detection of human immunodeficiency virus type 2 (HIV-2) antibodies employing polypeptide fragments of HIV-2 Gag.

In vitro diagnostic methods and kits for the detection of HIV-2-specific antibodies

Methods for producing the newly discovered HIV-2 retrovirus and its antigens are provided. The antigens are obtained from various HIV-2 retroviruses. The antigen compositions comprise a lysate of an HIV-2 retrovirus, a protein of an HIV-2 retrovirus, or a glycoprotein of an HIV-2 retrovirus. Specifically, the antigen composition can comprise p12, p16, p26, gp32, gp42, and gp140.

Methods for the preparation of human immunodeficiency virus type 2

Growing community of inventors

Paris, France

Solange Chamaret